More Good Results For Pembrolizumab; $0.77 Dividend Declared... At Merck

Merck has declared and paid more than 320 consecutive quarterly dividends, since the 1940s -- and today, it declared another $0.77 per share in dividends, payable on July 8; for shareholders of record June 17; ex-dividend date of June 17.

It also posted good, but immaterial results in 3 KEYNOTE-522. Here's that bit:

. . .The drugmaker said an interim analysis from the phase 3 KEYNOTE-522 trial of the anti-PD-1 therapy conducted by an independent Data Monitoring Committee found that Keytruda led to a statistically significant improvement in overall survival compared to pre-operative chemotherapy.

Merck noted the data is the first to show that an immunotherapy-based regimen has a survival benefit compared to chemotherapy alone in those with high-risk, early-stage triple-negative breast cancer. . . .

Now you know. Onward, grinning.

नमस्ते